Literature DB >> 29232252

Nicotinamide adenine dinucleotide and its related precursors for the treatment of Alzheimer's disease.

Nady Braidy1, Ross Grant2,3,4, Perminder S Sachdev1,5.   

Abstract

PURPOSE OF REVIEW: The current review discusses the biology and metabolism of the essential pyridine nucleotide nicotinamide adenine dinucleotide (NAD+) in the central nervous system. We also review recent work suggesting important neuroprotective effects that may be associated with the promotion of NAD+ levels through NAD+ precursors against Alzheimer's disease. RECENT
FINDINGS: Perturbations in the physiological homoeostatic state of the brain during the ageing process can lead to impaired cellular function, and ultimately leads to loss of brain integrity and accelerates cognitive and memory decline. Increased oxidative stress has been shown to impair normal cellular bioenergetics and enhance the depletion of the essential nucleotides NAD+ and ATP. NAD+ and its precursors have been shown to improve cellular homoeostasis based on association with dietary requirements, and treatment and management of several inflammatory and metabolic diseases in vivo. Cellular NAD+ pools have been shown to be reduced in the ageing brain, and treatment with NAD+ precursors has been hypothesized to restore these levels and attenuate disruption in cellular bioenergetics.
SUMMARY: NAD+ and its precursors may represent an important therapeutic strategy to maintain optimal cellular homoeostatic functions in the brain. NAD+ precursors are available in a variety of foods and may be translated to the clinic in the form of supplements.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29232252     DOI: 10.1097/YCO.0000000000000394

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  4 in total

1.  NAD+-mediated rescue of prenatal forebrain angiogenesis restores postnatal behavior.

Authors:  Sivan Subburaju; Sarah Kaye; Yong Kee Choi; Jugajyoti Baruah; Debkanya Datta; Jun Ren; Ashwin Srinivasan Kumar; Gabor Szabo; Dai Fukumura; Rakesh K Jain; Abdallah Elkhal; Anju Vasudevan
Journal:  Sci Adv       Date:  2020-10-09       Impact factor: 14.136

2.  Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease.

Authors:  Luke Whiley; Katie E Chappell; Ellie D'Hondt; Matthew R Lewis; Beatriz Jiménez; Stuart G Snowden; Hilkka Soininen; Iwona Kłoszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Jonathan R Swann; Abdul Hye; Simon Lovestone; Cristina Legido-Quigley; Elaine Holmes
Journal:  Alzheimers Res Ther       Date:  2021-01-09       Impact factor: 6.982

3.  Novel multifunctional iron chelators of the aroyl nicotinoyl hydrazone class that markedly enhance cellular NAD+ /NADH ratios.

Authors:  Zhixuan Wu; Duraippandi Palanimuthu; Nady Braidy; Nor Hawani Salikin; Suhelen Egan; Michael L H Huang; Des R Richardson
Journal:  Br J Pharmacol       Date:  2020-02-12       Impact factor: 8.739

Review 4.  Axonal Degeneration in AD: The Contribution of Aβ and Tau.

Authors:  Natalia Salvadores; Cristian Gerónimo-Olvera; Felipe A Court
Journal:  Front Aging Neurosci       Date:  2020-10-15       Impact factor: 5.750

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.